

Willsemi (603501 CH)

Sequential margin contraction indicates inventory digestions may persist till FY23E

Willsemi's 1H23 revenue and net profit were RMB8.9bn and RMB153mn, down 20% and 93% YoY, respectively. Margin continued to contract in 2Q23, suggesting the Company is making efforts to digest inventory. 2Q NP was negative again, failing to continue its profitability from 1Q. This has confirmed our previous prediction that "inventory digestion continues, however, not necessary a hint of market turnaround". ([link](#)) Looking forward, we think the de-stocking process is likely to persist till the end of the year, which will continue to hurt the Company's overall margin. Maintain HOLD, with adjusted TP at RMB85.

■ **Margin erosion in a declining market (mobile/security CIS).** 2Q's GPM dropped to 17.3% from 24.7% in 1Q23 and 33.3% in 2Q22, mainly due to weak mobile and security market demand and inventory digestion. Mobile/security sensor sales declined 45%/23% in 2022 and further declined 14%/25% YoY in 1H23. Inventory was RMB9.8bn, down by 30% from the peak in 3Q22. However, MOI (months of inventory) was still 6M. As de-stocking will continue into 2H23, we expect the overall GPM will remain under pressure. Once the inventory is back to normal level (3-4M), GPM can be expected to gradually return to previous 30% level.

■ **We are more conservative than the consensus as we expect a gradual recovery in 2024.** Counterpoint estimated smartphone shipment will decline 6% to 1.15bn in 2023, "worst in ten years", remain cautious on 1Q24 and show elevated risk of a delayed recovery into next year. Given Willsemi's large inventory and low consumer sentiment, we expect total revenue will decrease modestly by 5% in 2023. Recovery may come in 2024, when the Company's sales resume double-digit growth. 2024/25E revenue is estimated to reach RMB22.9bn/RMB26.4bn, which is 11%/14% lower than consensus.

■ **Maintain HOLD with TP adjusted to RMB85,** based on rollover 29.3x (unchanged) FY25E P/E. Current price is trading at 55x 24E P/E and 32x 25E P/E, which is fair valued. We think investors should watch Willsemi's GPM trend and inventory levels in the following quarters. Potential upside includes earlier-than-expected consumer demand recovery, better sales of new products.

Earnings Summary

(YE 31 Dec)	FY21A	FY22A	FY23E	FY24E	FY25E
Revenue (RMB mn)	24,104	20,078	19,184	22,944	26,423
YoY growth (%)	21.6	(16.7)	(4.5)	19.6	15.2
Gross margin (%)	34.5	30.8	22.8	26.8	30.7
Operating profit (RMB mn)	5,022	2,456	1,392	2,658	4,204
YoY growth (%)	63.9	(51.1)	(43.3)	90.9	58.2
Net profit (RMB mn)	4,476.2	1,448.5	357.9	2,034.4	3,467.3
YoY growth (%)	65.4	(67.6)	(75.3)	468.4	70.4
EPS (Reported) (RMB)	3.83	0.84	0.69	1.71	2.91
YoY growth (%)	61.1	(82.1)	22.4	103.4	70.4
P/E (x)	24.3	110.9	135.7	54.5	32.0
ROE (%)	27.5	5.5	4.2	9.4	13.9

Source: Company data, Bloomberg, CMBIGM estimates

HOLD (Maintain)

Target Price RMB85.00

(Previous TP RMB78.00)

Up/Downside (8.7%)

Current Price RMB93.15

China Technology

Lily YANG, Ph.D

(852) 3916 3716

lilyyang@cmbi.com.hk

Kevin ZHANG

(852) 3761 8727

kevinzhang@cmbi.com.hk

Stock Data

Mkt Cap (RMB mn)	109,791.0
Avg 3 mths t/o (RMB mn)	746.9
52w High/Low (RMB)	111.13/71.70
Total Issued Shares (mn)	1178.6

Source: FactSet

Shareholding Structure

Yu Renrong	30.3%
------------	-------


Source: Bloomberg

Share Performance

	Absolute	Relative
1-mth	-10.8%	-6.7%
3-mth	-2.3%	0.0%
6-mth	11.6%	17.4%

Source: FactSet

12-mth Price Performance



Source: FactSet

Related Reports

- 16/1/2023 Willsemi (603501 CH) – Preliminary 2022 results came in below estimate; Maintain HOLD ([link](#))
- 31/10/2022 Willsemi (603501 CH) – Sluggish 3Q22 performance; Downgrade to HOLD as near-term pressures may last longer ([link](#))
- 12/10/2022 China CIS Sector – Maintain long-term positive outlook; near-term challenges persist ([link](#))
- 16/8/2022 Willsemi (603501 CH) – 2Q results review: Recovery slowed down by weak mobile CIS ([link](#))
- 1/4/2022 China CIS Sector – Can non-mobile CIS strength offset handset weakness? We remain cautiously optimistic ([link](#))

Figure 1: CMBIGM estimates vs. consensus

RMB mn	CMBI estimates			Consensus			Diff (%)		
	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Revenue	19,184	22,944	26,423	20,754	25,911	30,875	-8%	-11%	-14%
Gross Profit	4,381	6,141	8,109	4,902	7,643	9,619	-11%	-20%	-16%
Operating Profit	882	2,200	3,770	1,616	3,779	5,385	-45%	-42%	-30%
Net profit	816	2,034	3,467	1,297	3,244	4,614	-37%	-37%	-25%
EPS (RMB)	0.686	1.708	2.911	1.163	2.846	3.909	-41%	-40%	-26%
Gross Margin	22.8%	26.8%	30.7%	23.6%	29.5%	31.2%	-0.8 ppt	-2.7 ppt	-0.5 ppt
Operating Margin	4.6%	9.6%	14.3%	7.8%	14.6%	17.4%	-3.2 ppt	-5 ppt	-3.2 ppt
Net Margin	4.3%	8.9%	13.1%	6.3%	12.5%	14.9%	-2 ppt	-3.7 ppt	-1.8 ppt

Source: Company data, CMBIGM estimates

Figure 2: Earnings revision

RMB mn	New		Old		Diff (%)	
	FY23E	FY24E	FY23E	FY24E	FY23E	FY24E
Revenue	19,184	22,944	21,661	24,178	-11%	-5%
Gross Profit	4,381	6,141	6,477	7,481	-32%	-18%
Operating Profit	882	2,200	3,271	3,694	-73%	-40%
Net profit	816	2,034	2,934	3,313	-72%	-39%
EPS (RMB)	0.686	1.708	2.455	2.769	-72%	-38%
Gross Margin	22.8%	26.8%	29.9%	30.9%	-7.1 ppt	-4.2 ppt
Operating Margin	4.6%	9.6%	15.1%	15.3%	-10.5 ppt	-5.7 ppt
Net Margin	4.3%	8.9%	13.5%	13.7%	-9.3 ppt	-4.8 ppt

Source: Company data, CMBIGM estimates

Financial Summary

INCOME STATEMENT	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec (RMB mn)						
Revenue	19,824	24,104	20,078	19,184	22,944	26,423
Cost of goods sold	(13,894)	(15,790)	(13,903)	(14,803)	(16,803)	(18,314)
Gross profit	5,930	8,314	6,175	4,381	6,141	8,109
Operating expenses	(2,865)	(3,292)	(3,719)	(2,989)	(3,483)	(3,905)
Selling expense	(371)	(515)	(516)	(439)	(502)	(551)
SG&A expense	(795)	(709)	(789)	(657)	(762)	(852)
R&D expense	(1,727)	(2,110)	(2,496)	(1,957)	(2,294)	(2,589)
Others	27	42	82	63	76	87
Operating profit	3,064	5,022	2,456	1,392	2,658	4,204
Other income	44	5	5	3	5	5
Other expense	(9)	(3)	(2)	(1)	(2)	(2)
Gain/loss on financial assets at FVTPL	(285)	(178)	(1,425)	(289)	(214)	(208)
Investment gain/loss	21	614	1,047	28	31	32
Other gains/(losses)	431	(103)	(186)	130	143	161
EBIT	3,267	5,358	1,895	1,263	2,621	4,193
Interest income	25	25	83	27	128	173
Interest expense	(297)	(410)	(559)	(494)	(546)	(593)
Net Interest income/(expense)	(272)	(385)	(475)	(467)	(418)	(420)
Other income/expense	(4)	29	96	(127)	0	0
Pre-tax profit	2,991	5,002	1,516	669	2,203	3,772
Income tax	(308)	(456)	(80)	(343)	(198)	(340)
After tax profit	2,683	4,546	1,436	326	2,004	3,433
Minority interest	(23)	70	(12)	(32)	(30)	(34)
Net profit	2,706	4,476	1,448	358	2,034	3,467
Net dividends	274	455	82	100	205	349

BALANCE SHEET	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec (RMB mn)						
Current assets	13,913	20,296	19,526	17,871	19,891	22,599
Cash & equivalents	5,423	7,630	3,995	7,112	9,947	13,134
Restricted cash	33	41	31	20	20	20
Account receivables	2,583	3,029	2,613	3,422	3,208	3,006
Inventories	5,274	8,781	12,356	6,697	6,024	5,800
Prepayment	151	220	236	218	261	300
Financial assets at FVTPL	13	15	14	34	34	34
Other current assets	436	579	280	367	397	306
Non-current assets	8,735	11,784	15,577	17,744	19,090	20,331
PP&E	1,995	2,045	2,540	2,977	3,405	3,823
Right-of-use assets	0	236	209	151	96	40
Deferred income tax	278	270	335	277	337	353
Investment in JVs & assos	185	1,015	2,499	2,932	2,964	2,987
Intangibles	1,509	1,604	2,018	2,133	2,256	2,349
Goodwill	2,800	2,998	3,169	3,870	3,870	3,870
Financial assets at FVTPL	1,178	2,576	2,964	3,258	3,605	3,988
Other non-current assets	791	1,041	1,842	2,144	2,558	2,922
Total assets	22,648	32,080	35,103	35,615	38,981	42,931
Current liabilities	6,845	8,700	10,373	8,703	9,084	8,916
Short-term borrowings	2,511	2,387	3,632	1,573	2,002	2,117
Account payables	2,544	3,956	2,281	2,991	2,809	2,509
Tax payable	705	589	145	107	139	141
Other current liabilities	753	1,364	3,926	3,742	3,744	3,744
Contract liabilities	110	149	125	131	157	181
Accrued expenses	221	255	263	158	233	224
Non-current liabilities	4,278	7,076	6,717	7,349	8,252	9,121
Long-term borrowings	3,182	3,448	2,750	3,245	4,044	4,687
Bond payables	0	2,250	2,347	2,347	2,347	2,347
Obligations under finance leases	0	179	145	133	153	165
Deferred income	279	304	423	487	501	570
Other non-current liabilities	817	895	1,052	1,138	1,207	1,352
Total liabilities	11,123	15,776	17,090	16,052	17,336	18,037
Share capital	868	876	1,185	1,189	1,191	1,191
Capital surplus	(255)	(742)	(769)	(769)	(769)	(769)

Retained earnings	3,895	8,049	8,572	9,288	11,241	14,503
Other reserves	6,731	8,015	9,030	9,697	9,943	9,964
Total shareholders equity	11,239	16,198	18,018	19,406	21,605	24,889
Minority interest	286	106	82	70	40	5
Total equity and liabilities	22,648	32,080	35,190	35,528	38,981	42,931

CASH FLOW	2020A	2021A	2022A	2023E	2024E	2025E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	2,683	4,546	958	804	2,004	3,433
Depreciation & amortization	765	927	1,045	1,204	1,386	1,655
Tax paid	159	4	51	122	(46)	53
Change in working capital	(691)	(3,569)	(5,352)	5,499	462	(112)
Others	429	284	1,303	492	558	750
Net cash from operations	3,345	2,192	(1,993)	8,121	4,364	5,779
Investing						
Capital expenditure	(1,133)	(1,122)	(2,259)	(1,743)	(1,932)	(2,130)
Acquisition of subsidiaries/ investments	(1,504)	(1,780)	(1,762)	(1,332)	(209)	(225)
Net proceeds from disposal of short-term investments	6	3	7	40	46	54
Others	0	0	(2)	14	(32)	(23)
Net cash from investing	(2,631)	(2,899)	(4,017)	(3,021)	(2,126)	(2,324)
Financing						
Dividend paid	(413)	(569)	(822)	(658)	(628)	(798)
Net borrowings	1,567	3,066	3,242	(1,746)	1,228	759
Proceeds from share issues	683	1,203	273	683	217	(0)
Others	(3)	(767)	(438)	(262)	(220)	(229)
Net cash from financing	1,835	2,932	2,255	(1,983)	597	(268)
Net change in cash						
Cash at the beginning of the year	3,116	5,423	7,630	3,995	7,112	9,947
Exchange difference	(241)	(18)	120	0	0	0
Others	2,548	2,226	(3,755)	3,117	2,835	3,187
Cash at the end of the year	5,423	7,630	3,995	7,112	9,947	13,134

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY	: Stock with potential return of over 15% over next 12 months
HOLD	: Stock with potential return of +15% to -10% over next 12 months
SELL	: Stock with potential loss of over 10% over next 12 months
NOT RATED	: Stock is not rated by CMBIGM
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong. Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.